Regeneron Pharmaceuticals Inc vs United Airlines Holdings Inc — how do they compare? Regeneron Pharmaceuticals Inc trades at $807.6 (market cap $83.43B), while United Airlines Holdings Inc trades at $107.36 (market cap $35.13B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 2.4× United Airlines Holdings Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.46% dividend while United Airlines Holdings Inc pays none. Which is the better fit depends on your goals.
| REGN | UAL | |
|---|---|---|
Market Cap | $83.43B | $35.13B |
Sector | Health | Industrials |
52-Week High | $852.03 | $136.11 |
52-Week Low | $555.51 | $85.21 |
Enterprise Value | $78.14B | $52.16B |
Dividend Yield | 0.46% | — |
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
United Airlines (UAL) trades at $108.24, down 2.82% today, with a bearish technical signal but strong fundamentals including a P/E of 10.13 and net income margin of 5.56%. The company has beaten EPS estimates for three consecutive quarters and announced its largest international expansion, adding 10 new routes for 2027. Cash flow trends show volatility, with 2025 net cash flow negative at -$2.86 billion but projected to turn positive in 2026.
The outlook is mixed: analyst consensus is strongly bullish with a $168.96 price target, but high jet fuel costs and geopolitical risks pose headwinds. Earnings growth and international expansion are key catalysts, while debt levels and operational efficiency remain areas to watch for sustained shareholder value.
Trailing returns across standard periods
Latest headlines on both assets
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →United Airlines is a major U.S. network carrier. United's hubs include San Francisco, Chicago, Houston, Denver, Los Angeles, New York/Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international travel than legacy peers.
Read more on UAL →